Senate Majority Leader Bill Frist (R-TN) called on pharmaceutical marketers to restrict their direct-to-consumer advertising for new drugs.
Frist, a medical doctor, urged companies to voluntarily hold back for two years on advertising new medications. He also called for a review by the General Accounting Office on The Food and Drug Administration
Network
